Stock Analiz

Onconetix, Inc. ONCO

Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026

$3.21Market cap $2M
Open the interactive analysis →

Onconetix, Inc. (ONCO) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $645824 and net income of -$10M, a net margin of -1578.8%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.0, a 5-year average ROIC of -295%.

About Onconetix

Onconetix is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 5 years in our data. Its share count rose by 25880% over three years (dilution for shareholders).

Score: 1.0 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.0
Forward P/E—
P/FCF—
P/S3.3
P/B0.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-479.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-67.7%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-22677.6%
ROIC (5-yr avg.)-294.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$645824$815371$3M$58465——
Net income-$10M-$14M-$59M-$37M-$13M-$3M
Free cash flow-$10M—-$11M-$14M-$9M-$2M
EPS (diluted)$-17.16$-16.56$-1823.39$-7433.19$-3739.97$-4283.97
Net margin-1578.8%-1721.0%-2325.2%-63986.5%——
ROIC—-89.2%-308.5%-840.9%-47.6%-186.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Onconetix’s P/E ratio?

About 0.0, based on the last twelve months of diluted earnings per share.

Does Onconetix pay a dividend?

Not currently.

Is Onconetix a good stock to buy?

We do not give buy or sell advice. Onconetix scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.